David Henderson, MD
Psychiatry · Boston, MANPI 1699759076
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,800 of the $27,642 with a category attached, or 97.0%. 4 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 56.4% of the total. Reporting peaked in 2021 at $10,400 and has fallen 64.4% since, to $3,700 in 2024. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $2512.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$16K
- Alkermes, Inc.$8K
- Sumitomo Pharma America, Inc.$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
Across 17 payments — averaging $4927.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche TCRC, Inc.$49K
- Boehringer Ingelheim$35K
What the payments were for
- Consulting fees$26,80097%
- Travel & lodging$6872%
- Food & beverage$1551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 3 | $15,600 |
| Alkermes, Inc. | 6 | $8,342 |
| Sumitomo Pharma America, Inc. | 1 | $1,850 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,850 |
How this compares
$27,642 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 32 | $4,261 |
| Quetiapine Fumarate | 38 | $2,966 |
| Zolpidem Tartrate ErZolpidem Tartrate | 11 | $1,117 |
| Clonazepam | 39 | $704 |
| Clozapine | 11 | $609 |
| Mirtazapine | 27 | $607 |
| Gabapentin | 21 | $606 |
| Divalproex Sodium | 24 | $521 |
| Lorazepam | 12 | $203 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $163 |
| Trazodone Hcl | 15 | $56 |
| Zolpidem Tartrate | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Boston
- Ximena Sanchez-SamperBoston$258K
- George PapakostasBoston$170K
- Maurizio FavaBoston$120K
- Andrew NierenbergBoston$94K
- Lee GoldsteinBoston$90K
- Gary SachsBoston$81K
- Dan IosifescuBoston$61K
- Lee CohenBoston$51K
- Michael OstacherBoston$39K
- Cristina MontalvoBoston$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.